Hereditary Angioedema Therapeutics Global Market Report 2025

Description

Hereditary angioedema (HAE) therapeutics pertain to the treatment of an autosomal dominant condition caused by a deficiency or malfunction of the C1-inhibitor protein. Symptoms of hereditary angioedema include angioedema-related upper airway, cutaneous, and/or gastrointestinal complaints.

The main drug classes of hereditary angioedema therapeutics include C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, kallikrein inhibitor, and others. C1 Esterase Inhibitor is a protein present in the fluid portion of blood that regulates the complement system's protein C1. These therapeutics are administered through intravenous, subcutaneous, and oral routes and are distributed via hospital pharmacies, retail pharmacies, and others. The application of hereditary angioedema therapeutics includes prophylaxis and on-demand treatment.

The hereditary angioedema therapeutics market research report is one of a series of new reports from The Business Research Company that provides hereditary angioedema therapeutics market statistics, including hereditary angioedema therapeutics industry global market size, regional shares, competitors with a hereditary angioedema therapeutics market share, detailed hereditary angioedema therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary angioedema therapeutics industry. This hereditary angioedema therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hereditary angioedema therapeutics market size has grown rapidly in recent years. It will grow from$6.68 billion in 2024 to $7.84 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to improved diagnosis and awareness, treatment access expansion, research and development initiatives, patient advocacy and education, and regulatory approvals

The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to $16.11 billion in 2029 at a compound annual growth rate (CAGR) of 19.7%. The growth in the forecast period can be attributed to advancements in targeted therapies, global market expansion, gene therapy developments, personalized medicine trends, and collaboration in research and treatment. Major trends in the forecast period include global access initiatives, health economic outcomes research, early intervention strategies, and pediatric HAE therapeutics.

The anticipated rise in the prevalence of hereditary angioedema is expected to drive the growth of the hereditary angioedema market in the future. Hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent severe swelling of the skin and mucous membranes, affects approximately 1 in every 50,000 individuals globally, with prevalence estimates ranging from 1,10,000 to 1,150,000. These episodes result in 15,000 to 30,000 emergency room visits annually in the US alone. The increasing incidence of hereditary angioedema is a significant factor propelling the growth of the hereditary angioedema market.

The rising healthcare expenditure is projected to enhance the growth of the hereditary angioedema therapeutics market in the future. Healthcare expenditure refers to the total resources, including financial investments, allocated for healthcare goods and services within a specific timeframe in a defined geographical area. Increased healthcare spending facilitates greater investment in research and development aimed at understanding the underlying causes of hereditary angioedema and creating innovative therapeutic solutions. For instance, in December 2022, the Centers for Medicare & Medicaid Services, a U.S.-based federal agency, reported that U.S. healthcare spending increased by 4.1% to reach $4.5 trillion in 2022, surpassing the 3.2% growth seen in 2021. Therefore, the rise in healthcare expenditure is propelling the growth of the hereditary angioedema therapeutics market.

A notable trend gaining traction in the hereditary angioedema therapeutics market is the emphasis on product innovation. Leading companies in this market are actively involved in the development of groundbreaking products, including ligand-conjugated (LICA) investigational antisense medicine and gene therapy, to reinforce their market position. In a significant development, Intellia Therapeutics, a clinical-stage biotechnology company based in the US, introduced an Investigational New Drug (IND) named NTLA-2002 in March 2023. This innovative therapy, approved by the United States Food and Drug Administration for hereditary angioedema treatment, allows the company's ongoing Phase 1/2 trial to incorporate the US into the global Phase 2 segment. NTLA-2002, a candidate for in vivo genome editing, aims to permanently lower plasma kallikrein protein activity and prevent hereditary angioedema attacks after a single dose of therapy through the inactivation of the target gene, kallikrein B1 (KLKB1).

Key companies in the hereditary angioedema (HAE) therapeutics market are focusing on developing innovative treatments, such as oral plasma kallikrein inhibitors, to improve patient management and provide effective on-demand solutions for alleviating HAE attacks. These oral medications work by inhibiting the enzyme plasma kallikrein, which helps manage and lessen the severity of hereditary angioedema episodes. For example, in September 2024, KalVista Pharmaceuticals, a U.S.-based biopharmaceutical company, received a new drug application approval from the U.S. Food and Drug Administration for Sebetralstat. This treatment aims to provide HAE patients with a more convenient, non-invasive alternative to intravenous or subcutaneous therapies. It addresses the increasing demand for rapid and effective oral treatments that can be administered immediately during an HAE attack, thereby enhancing overall patient outcomes and quality of life.

In February 2023, Takeda Pharmaceutical Company acquired Nimbus Lakshmi, Inc. from Nimbus Therapeutics, LLC. The acquisition, involving an undisclosed amount, enhances Takeda's late-stage pipeline, contributing to portfolio expansion and broadening its impact across multiple indications. Nimbus Lakshmi is a US-based company specializing in Tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hereditary angioedema therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hereditary angioedema therapeutics market includes revenues earned by entities by diagnosis and evaluation, treatment, management of hereditary angioedema. The market value includes the value of related goods sold by the service provider or included within the service offering. he hereditary angioedema therapeutics market also includes of sales of tranexamic acid, danazol, intravenous and subcutaneous nano filtered purified plasma-derived human C1 esterase inhibitor concentrate, and lanadelumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hereditary Angioedema Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hereditary angioedema therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hereditary angioedema therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hereditary angioedema therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: C1 Esterase Inhibitor; Selective Bradykinin B2 Receptor Antagonist; Kallikrein Inhibitor; Other Drug Classes
2) By Route of Administration: Intravenous; Subcutaneous; Oral
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
4) By Application: Prophylaxis; On-demand
Subsegments:
1) By C1 Esterase Inhibitor: Plasma-Derived; Recombinant
2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant
3) By Kallikrein Inhibitor: Ecallantide; Lanadelumab
4) By Other Drug Classes: Emerging Therapies
Companies Mentioned: Sanofi S.A.; Pharming Healthcare Inc.; Attune Pharmaceuticals Inc.; Adverum Biotechnologies Inc.; Arrowhead Pharmaceuticals Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r24198

1. Executive Summary

2. Hereditary Angioedema Therapeutics Market Characteristics

3. Hereditary Angioedema Therapeutics Market Trends And Strategies

4. Hereditary Angioedema Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Hereditary Angioedema Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Hereditary Angioedema Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Hereditary Angioedema Therapeutics Market Growth Rate Analysis
5.4. Global Hereditary Angioedema Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Hereditary Angioedema Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Hereditary Angioedema Therapeutics Total Addressable Market (TAM)

6. Hereditary Angioedema Therapeutics Market Segmentation

6.1. Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
C1 Esterase Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Kallikrein Inhibitor
Other Drug Classes
6.2. Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous
Subcutaneous
Oral
6.3. Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Other Distribution Channels
6.4. Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prophylaxis
On-demand
6.5. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of C1 Esterase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plasma-Derived
Recombinant
6.6. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Icatibant
6.7. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ecallantide
Lanadelumab
6.8. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Emerging Therapies

7. Hereditary Angioedema Therapeutics Market Regional And Country Analysis

7.1. Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hereditary Angioedema Therapeutics Market

8.1. Asia-Pacific Hereditary Angioedema Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hereditary Angioedema Therapeutics Market

9.1. China Hereditary Angioedema Therapeutics Market Overview
9.2. China Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hereditary Angioedema Therapeutics Market

10.1. India Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hereditary Angioedema Therapeutics Market

11.1. Japan Hereditary Angioedema Therapeutics Market Overview
11.2. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hereditary Angioedema Therapeutics Market

12.1. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hereditary Angioedema Therapeutics Market

13.1. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hereditary Angioedema Therapeutics Market

14.1. South Korea Hereditary Angioedema Therapeutics Market Overview
14.2. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hereditary Angioedema Therapeutics Market

15.1. Western Europe Hereditary Angioedema Therapeutics Market Overview
15.2. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hereditary Angioedema Therapeutics Market

16.1. UK Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hereditary Angioedema Therapeutics Market

17.1. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hereditary Angioedema Therapeutics Market

18.1. France Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hereditary Angioedema Therapeutics Market

19.1. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hereditary Angioedema Therapeutics Market

20.1. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hereditary Angioedema Therapeutics Market

21.1. Eastern Europe Hereditary Angioedema Therapeutics Market Overview
21.2. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hereditary Angioedema Therapeutics Market

22.1. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hereditary Angioedema Therapeutics Market

23.1. North America Hereditary Angioedema Therapeutics Market Overview
23.2. North America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hereditary Angioedema Therapeutics Market

24.1. USA Hereditary Angioedema Therapeutics Market Overview
24.2. USA Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hereditary Angioedema Therapeutics Market

25.1. Canada Hereditary Angioedema Therapeutics Market Overview
25.2. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hereditary Angioedema Therapeutics Market

26.1. South America Hereditary Angioedema Therapeutics Market Overview
26.2. South America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hereditary Angioedema Therapeutics Market

27.1. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hereditary Angioedema Therapeutics Market

28.1. Middle East Hereditary Angioedema Therapeutics Market Overview
28.2. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hereditary Angioedema Therapeutics Market

29.1. Africa Hereditary Angioedema Therapeutics Market Overview
29.2. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hereditary Angioedema Therapeutics Market Competitive Landscape And Company Profiles

30.1. Hereditary Angioedema Therapeutics Market Competitive Landscape
30.2. Hereditary Angioedema Therapeutics Market Company Profiles
- 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Pharming Healthcare Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Attune Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Adverum Biotechnologies Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Arrowhead Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hereditary Angioedema Therapeutics Market Other Major And Innovative Companies

31.1. Ionis Pharmaceuticals Inc.
31.2. BioCryst Pharmaceuticals Inc.
31.3. CSL Behring LLC
31.4. KalVista Pharmaceutical Inc.
31.5. CENTOGENE N.V.
31.6. GlaxoSmithKline plc.
31.7. Eli Lilly and Company
31.8. Amgen Inc.
31.9. AbbVie Inc.
31.10. Incyte Corporation
31.11. BioMarin Pharmaceutical Inc.
31.12. Dyax Corp.
31.13. Salix Pharmaceuticals Inc.
31.14. Pharvaris N.V.
31.15. Innovent Biologics Inc.

32. Global Hereditary Angioedema Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hereditary Angioedema Therapeutics Market

34. Recent Developments In The Hereditary Angioedema Therapeutics Market

35. Hereditary Angioedema Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Hereditary Angioedema Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Hereditary Angioedema Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Hereditary Angioedema Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer